PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirmala Jain PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirmala Jain PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Jain PANACEA BIOTEC LTD. - 531349 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Rajesh Jain PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company from April 01, 2023 till completion of 48 hours from the announcement to the Stock Exchanges regarding Audited financial results of the Company for the quarter and financial year ended March 31, 2023. The date of meeting of the Board of Directors to approve the Audited financial results of the Company for the quarter and financial year ended March 31, 2023, shall be informed in due course
Johnson & Johnson's dengue antiviral drug shows positive results
Around November, the ICMR sought the drug regulator's nod for phase-3 trials of a vaccine candidate it developed with drugmakers SII and Panacea Biotec PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialized During February, 2023
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we would like to inform you that no share has been dematerialized during the month of February, 2023. A copy of the certificate obtained from the Company's RTA viz. Skyline Financial Services Pvt. Ltd., regarding shares dematerialized as on February 28, 2023 is also enclosed as Annexure -1 PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated February 14, 2023 for approving the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company for the Quarter and Nine Months ended December 31, 2022 and pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the Extract of Statement of aforesaid Unaudited Financial Results published in the newspapers on February 15, 2023 PANACEA BIOTEC LTD. - 531349 - Revised Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31, 2022
In continuation to our letter dated February 14, 2023, we would like to inform you that we have noted that due to inadvertent typographical/clerical error, the consolidated figures for Depreciation and amortisation expenses and Finance costs for the nine months ended December 31, 2022 as mentioned in the Statement of Standalone and Consolidated Financial Results (Unaudited) for the quarter and nine months ended December 31, 2022 were replaced with each other as a result of which the consolidated figures for these items for the quarter and nine months ended December 31, 2022 got mentioned incorrect.
